Agostino Gemelli University Hospital Foundation IRCCS

What Agostino Gemelli University Hospital Foundation IRCCS does

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is a private non-profit university hospital foundation headquartered in Rome, Italy, affiliated with Università Cattolica del Sacro Cuore. It operates Italy's largest private non-profit hospital facility, with 1,526 beds organized across 8 Departments and 135 Operating Units, delivering tertiary and quaternary care including surgery, emergency medicine, transplantation, oncology, women's and children's health, geriatric medicine, and rare-disease treatment. Annual operational volumes include 94,919 discharges, 53,701 surgeries, 82,076 emergency-department visits, 4,110 births, and 10.5M outpatient services, with a workforce of 5,322 employees and 2,500+ scientific publications per year.

The hospital's technology stack centers on advanced oncology and theranostics. In December 2025 it launched FPG 360, an in-house liquid biopsy testing service powered by Guardant360 CDx for comprehensive genomic profiling; it operates GemelliART for advanced radiation therapy, a Theranostic Oncology Center (TOC) for radiopharmaceutical theranostics, the Gemelli Science and Technology Park (GSTeP) for translational research, and an ISO 9001:2015-certified research biobank integrated into BBMRI-IT and BBMRI-ERIC. It is a clinical partner in three IHI-funded European theranostics programs (ACCELERATE.EU for astatine-211 radiotheranostics, ILLUMINATE for Lu-177-PSMA prostate-cancer patient selection using metabolic-MRI, and Thera4Care for pan-European theranostics infrastructure). The hospital holds multiple international accreditations (JCI, FACT, JACIE, EFI, IASIOS, ISO 9001/45001/50001).

The revenue model blends Italy's SSN-funded public inpatient and outpatient services with private-pay (Attivit\u00e0 Privata) consultations, home-care (Gemelli a Casa) subscriptions, and licensing/royalty-style inflows from clinical trials, IHI grants, and biotech-pharma research collaborations. GTM is channel-partner-driven for diagnostics (Guardant Health partnership for FPG 360) and consortium-based for research (IHI, EBMT, BBMRI-ERIC). Customer segments split broadly across the general Italian population (SSN), oncology patients (theranostics and liquid biopsy), women and pediatric patients, elderly/aging patients, and academic/clinical-research partners; pricing for SSN services follows national tariff schedules with standard co-pays, while private-pay pricing is not publicly disclosed.

Name

Agostino Gemelli University Hospital Foundation IRCCS

Legal name

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Website

https://policlinicogemelli.it

Company type

Private

Founded year

1964

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is Italy's largest private non-profit university hospital, providing tertiary and quaternary care, oncology, transplant, and theranostics services through 1,526 beds in Rome, primarily funded via Italy's national health system and supported by an academic affiliation with Universit\u00e0 Cattolica del Sacro Cuore.

Ownership category

akta.pro rank

Product category

Academic Medical Center / Tertiary Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Specialty (except Psychiatric and Substance Abuse) Hospitals (6223), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), General Medical and Surgical Hospitals (6221)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062), Services-Hospitals (8060), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Transplant Specialty Hospitals (HLAFAHAE)

Keywords

• University hospital services
• Oncology diagnostics
• Precision medicine
• Translational research
• Advanced radiation therapy

Headquarters

HQ city

Roma

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. National Health Service (SSN) Clinical Services: The hospital operates as a public/university hospital providing healthcare services under Italy's Servizio Sanitario Nazionale (SSN), generating revenue through government-funded patient care including inpatient admissions, surgeries, emergency services, outpatient consultations, and diagnostic procedures.
2. Private/Paying Patient Services: Private medical services (Attività Privata) offered to patients choosing non-SSN pathways, including specialist consultations, diagnostic tests, and treatments on a private-pay basis.
3. Gemelli a Casa (Home Care Services): Private home healthcare services extending hospital care to patients' homes.
4. Scientific Research and Clinical Trials: Revenue generated through clinical trials, research grants (e.g., IHI funding for theranostics projects), and scientific collaborations that contribute to funding research activities and infrastructure.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels8 records

Core offering

Fondazione Policlinico Universitario Agostino Gemelli IRCCS operates Italy's largest private non-profit university hospital with 1,526 beds across 8 Departments and 135 Operating Units, delivering tertiary and quaternary healthcare services including oncology, theranostics, advanced radiation therapy, organ transplantation, and precision diagnostics. The hospital serves as the academic medical center for Università Cattolica del Sacro Cuore and runs specialized programs such as FPG 360 liquid biopsy testing, the Comprehensive Cancer Center, the Theranostic Oncology Center (TOC), GemelliART radiation therapy, and an ISO-certified research biobank.

Product overview

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is a university hospital providing comprehensive healthcare services through 8 Departments and 135 Operating Units. The hospital offers specialized diagnostic and treatment services including liquid biopsy testing (FPG 360), advanced radiation therapy (GemelliART), theranostics (TOC), and operates multiple specialized centers covering oncology, digestive diseases, aging medicine, and research biobanking. The hospital is affiliated with Università Cattolica del Sacro Cuore and serves as a major academic medical center in Rome, Italy.

Differentiator

Problem solved

Functional benefit

Products and services

• FPG 360 Liquid Biopsy Testing Service In-house liquid biopsy testing service based on Guardant360 CDx technology, providing comprehensive genomic profiling for cancer patients in Italy without requiring international sample transfers.
• Comprehensive Cancer Center Multi-disciplinary oncology center providing advanced cancer diagnosis, treatment, clinical trials, and translational research across the hospital.
• Theranostic Oncology Center (TOC) Center dedicated to theranostics, combining diagnostic detection with therapeutic destruction of cancer cells using radiopharmaceuticals such as Lu-177-PSMA and astatine-211.
• GemelliART (Advanced Radiation Therapy) Advanced radiation therapy center offering innovative radiation treatment technologies for oncology patients.
• Gemelli a Casa (Home Care Services) Private home healthcare services extending hospital-level care to patients in their homes for discharged patients and those requiring ongoing medical supervision.
• Biobanca di Ricerca (Research Biobank) ISO 9001:2015 certified institutional biobank collecting, preserving, and distributing biological samples with associated clinical data for translational research, integrated with BBMRI-IT and BBMRI-ERIC networks.
• Private Pay Services (Attivit\u00e0 Privata) Private medical services offered in parallel with SSN services for patients choosing faster or specific private pathways, including specialist consultations, diagnostic tests, and treatments on a private-pay basis.
• Umbilical Cord Blood Bank (Banca del Cordone Ombelicale UNICATT) FACT-accredited cord blood bank providing collection, processing, cryopreservation, and distribution of cord blood units for clinical use, coordinated by CNT and CNS.
• CeMI (Centro di Medicina dell'Invecchiamento) Center for medicine of aging providing specialized care for elderly patients including management of multi-morbidity, rehabilitation, cognitive decline, and age-related chronic diseases.
• Centro Antiveleni (Poison Control Center) Poison control and emergency toxicology center providing consultation and clinical management for poisoning and toxic exposure cases.

Named customers2 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

13 partnerships are on record, tiered core and flagship.

• Guardant HealthcoreStrategic or Co-development Partner · 9 December 2025Guardant Health and Policlinico Gemelli launched FPG 360, an in-house liquid biopsy testing service based on Guardant360 CDx technology at Fondazione Policlinico Universitario Agostino Gemelli in Rome. This is among the first dedicated liquid biopsy testing facilities in Italy housed within a hospital system, enabling Italian cancer patients to access comprehensive genomic profiling without sending samples abroad.
• IHI (Innovative Health Initiative) - ACCELERATE.EUflagshipStrategic or Co-development Partner · 2 December 2025IHI is funding ACCELERATE.EU, a European project developing astatine-211 radiotheranostics for aggressive cancers with poor prognoses. A pilot study for recurrent brain cancer is launching mid-2026 and a Phase I breast cancer study is planned for 2027. Gemelli is participating as a key clinical site in this theranostics development initiative.
• IHI (Innovative Health Initiative) - ILLUMINATEflagshipStrategic or Co-development Partner · 2 December 2025IHI is funding the ILLUMINATE project aimed at improving patient selection for Lu-177-PSMA prostate cancer treatment using metabolic-MRI technology. Gemelli participates as a clinical and research partner in this European initiative to advance precision prostate cancer theranostics.
• IHI (Innovative Health Initiative) - Thera4CareflagshipStrategic or Co-development Partner · 2 December 2025IHI is funding Thera4Care, a project building European infrastructure to position the EU as a global leader in theranostics. Gemelli contributes as a key institution in this pan-European effort to develop theranostics capabilities and standards.
• VHIO (Vall d'Hebron Institute of Oncology), BarcelonaflagshipStrategic or Co-development PartnerEuropean academic hospital partnership for precision oncology. Gemelli's collaboration with Guardant Health adds to existing Guardant partnerships with leading European academic hospitals including VHIO in Barcelona and The Royal Marsden Hospital in London.
• The Royal Marsden Hospital, LondonflagshipStrategic or Co-development PartnerEuropean academic hospital partnership for precision oncology. Gemelli's Guardant Health collaboration adds to existing partnerships with The Royal Marsden Hospital in London and VHIO in Barcelona, forming a network of leading European precision oncology centers.
• Università Cattolica del Sacro CuoreflagshipStrategic or Co-development PartnerGemelli is the seat of the Faculty of Medicine and Surgery of Università Cattolica del Sacro Cuore. This academic partnership forms the foundation of the hospital's research, teaching, and clinical care mission, providing a continuous pipeline of medical professionals and driving scientific output of 2,500+ publications annually.
• ASL Roma 1coreChannel Partner/ Reseller/ DistributorPartnership with ASL Roma 1 for vaccination services. The agreement ensures free vaccination for fragile patients at Policlinico Gemelli, covering influenza, COVID-19, pneumococcal, meningococcal, and Herpes zoster vaccines.
• Istituto ToniolocoreStrategic or Co-development PartnerFounding entity of Fondazione Policlinico Universitario Agostino Gemelli IRCCS, alongside Università Cattolica del Sacro Cuore. Istituto Toniolo is a founding partner providing institutional and ideological foundation rooted in Catholic social teaching.
• IHI (Innovative Health Initiative)flagshipStrategic or Co-development PartnerIHI (Innovative Health Initiative) is a European public-private partnership funding three theranostics projects (ACCELERATE.EU, ILLUMINATE, and Thera4Care) in which Gemelli participates as a key clinical and research partner to advance theranostics combining diagnostic detection with therapeutic destruction of cancer cells.
• European Blood and Marrow Transplantation (EBMT)coreStrategic or Co-development PartnerGemelli's Hematopoietic Stem Cell Transplantation Program is accredited under EBMT standards, operating within the JACIE accreditation framework for stem cell collection, processing, and transplantation.
• BBMRI-ERIC (Biobanking and Biomolecular Resources Research Infrastructure)coreStrategic or Co-development PartnerGemelli's Biobanca joined the national BBMRI-IT node and the European BBMRI-ERIC infrastructure (ID: IT_1590093451396856) in March 2023, enabling sample and data sharing within a European biobanking network.
• Centro Nazionale Trapianti (CNT) and Centro Nazionale Sangue (CNS)coreStrategic or Co-development PartnerTechnical and scientific coordination for the Umbilical Cord Blood Bank (Banca del Cordone Ombelicale UNICATT) is provided by CNT and CNS, ensuring compliance with national and international standards for cord blood banking.

Scale indicators17 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Istituto Europeo di Oncologia (IEO): Milan-based monothematic oncology IRCCS founded by Umberto Veronesi. Directly comparable on cancer care delivery model; a primary Italian competitor for complex oncology referrals and clinical trial activity.
• IRCCS Ospedale San Raffaele: Milan-based Italian IRCCS university hospital operated under Università Vita-Salute San Raffaele with strong oncology, gene therapy, and translational research. Closest domestic peer by structure: Italian private non-profit IRCCS, university-affiliated, oncology-heavy, competing for SSN-funded tertiary referrals and EU research funding.
• IRCCS Humanitas Research Hospital: Milan-based Italian IRCCS affiliated with Humanitas University, with a major Comprehensive Cancer Center and active EU research portfolio. Closely comparable in structure (private non-profit IRCCS, university hospital, oncology-led, near-peer in Newsweek rankings).
• The Royal Marsden Hospital: London-based specialist cancer hospital explicitly named in the data as a Guardant Health partner alongside Gemelli. Comparable as a research-intensive, tertiary/quaternary cancer and theranostics center with comparable international brand strength and academic affiliation (with the Institute of Cancer Research).
• Vall d'Hebron Institute of Oncology (VHIO): Barcelona translational oncology center explicitly named in the data as a Guardant Health partner alongside Gemelli. Comparable as a precision-oncology research hospital with similar liquid-biopsy, clinical-trial, and theranostics ambitions embedded in a large public university hospital system.

Broad incumbents

• Heidelberg University Hospital (Universitätsklinikum Heidelberg): German academic medical center recognized for oncology, radiation therapy, and translational research at the National Center for Tumor Diseases (NCT). Comparable as a European university hospital with a Comprehensive Cancer Center, theranostics and precision-oncology focus, and national-reference role.
• Universitätsspital Zürich (University Hospital Zurich): Large Swiss academic medical center with strong oncology, transplantation, and translational research profiles. Comparable as a European university hospital anchoring EU/international research consortia and competing for medical-tourism and complex tertiary referrals.
• MD Anderson Cancer Center: World-leading US specialty oncology hospital and global benchmark for theranostics, liquid biopsy and precision oncology. Comparable as a global reference Comprehensive Cancer Center that anchors international trial pipelines and industry partnerships analogous to Gemelli's IOC/TOC ambitions.
• Karolinska University Hospital: Stockholm-based university hospital with strong oncology, regenerative medicine, and translational research. Comparable as a publicly funded, research-intensive European academic medical center that competes for EU precision-oncology and theranostics consortium positions.
• Charité - Universitätsmedizin Berlin: One of Europe's largest university hospitals, affiliated with Humboldt and Freie Universität Berlin. Comparable as a comprehensive academic medical center with strong translational research, oncology, theranostics, and biobanking programs targeting EU consortium funding.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/policlinicogemelli
• YouTubeyoutube.com/channel/policlinicogemelli
• Facebookfacebook.com/policlinicogemelli
• LinkedInlinkedin.com/company/fondazione-policlinico-universitario-agostino-gemelli-irccs
• Instagraminstagram.com/policlinicogemelli

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Agostino Gemelli University Hospital Foundation IRCCS